A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer
This study is a multicenter, open-label, multi-cohort phase II clinical trials to evaluate the efficacy and safety of TQB3616 capsules combined with Fulvestrant injection in subjects with HR-positive and HER2-negative advanced and/or metastatic breast cancer, including Cohort 1 and Cohort 2. Each cohort will enroll 30-60 cases.
HR-positive, HER2-negative Advanced Breast Cancer
DRUG: TQB3616 capsules|DRUG: Fulvestrant injection
Overall response rate (ORR) assessed by investigator, ORR defined as percentage of participants achieving complete response (CR) and partial response (PR), recorded from the first dose until the first documented progressive disease (PD) or death from any cause, based on investigator., Baseline up to 24 months
Progression free survival (PFS), PFS defined as the time from first dose until the first documented progressive disease (PD) or death from any cause., Baseline up to 24 months|Overall survival (OS), OS defined as the time from first dose to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive., Baseline up to 24 months]|Clinical benefit rate (CBR), Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD)., Baseline up to 24 months|Duration of Response (DOR), The time when the participants first achieved complete or partial remission to disease progression., Baseline up to 24 months
This study is a multicenter, open-label, multi-cohort phase II clinical trials to evaluate the efficacy and safety of TQB3616 capsules combined with Fulvestrant injection in subjects with HR-positive and HER2-negative advanced and/or metastatic breast cancer, including Cohort 1 and Cohort 2. Each cohort will enroll 30-60 cases.